News Medical on MSN2d
Vimseltinib Approved by FDA for Tenosynovial Giant Cell TumorThe FDA has approved vimseltinib for tenosynovial giant cell tumor (TGCT) based on the phase 3 MOTION trial led by Dr.
Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, ...
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the ...
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback